By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login
Logo for company Broncus Holding Corporation

Broncus Holding Corporation (2216.HK)

HKSE Market Data in HKD, Fundamentals in USD
$3.17
+$0.20
+6.73%
Last Update: 1 Sept 2025, 03:34
$1.67B
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
$0.46 - $3.70
52 Week Range

2216.HK Stock Price Chart

Explore Broncus Holding Corporation interactive price chart. Choose custom timeframes to analyze 2216.HK price movements and trends.

2216.HK Company Profile

Discover essential business fundamentals and corporate details for Broncus Holding Corporation (2216.HK) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Medical - Devices

IPO Date

24 Sept 2021

Employees

200.00

CEO

Hong Xu

Description

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

2216.HK Financial Timeline

Browse a chronological timeline of Broncus Holding Corporation corporate events including earnings releases, dividend announcements, and stock splits.

Earnings released on 31 Dec 2024

EPS came in at -$0.12 , while revenue for the quarter reached $34.39M .

Earnings released on 30 Aug 2024

EPS came in at -$0.13 , while revenue for the quarter reached $28.93M .

Earnings released on 29 Mar 2024

EPS came in at -$0.21 falling short of the estimated -$0.16 by -36.67%, while revenue for the quarter reached $39.21M , missing expectations by -61.48%.

Earnings released on 31 Aug 2023

EPS came in at -$0.24 falling short of the estimated -$0.24 by -0.48%, while revenue for the quarter reached $41.01M , beating expectations by +0.63%.

Earnings released on 29 Mar 2023

EPS came in at -$0.19 surpassing the estimated -$0.47 by +59.14%, while revenue for the quarter reached $48.34M , missing expectations by -67.03%.

Earnings released on 30 Aug 2022

EPS came in at -$0.26 falling short of the estimated -$0.24 by -9.75%, while revenue for the quarter reached $25.25M , missing expectations by -14.49%.

Earnings released on 31 Dec 2021

EPS came in at -$4.07 falling short of the estimated -$0.55 by -645.56%, while revenue for the quarter reached $62.67M , beating expectations by +13.67%.

Earnings released on 30 Jun 2021

EPS came in at -$1.45 , while revenue for the quarter reached $22.15M .

Earnings released on 31 Dec 2020

EPS came in at -$1.16 , while revenue for the quarter reached $18.81M .

2216.HK Stock Performance

Access detailed 2216.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run